Arch Biopartners Inc. (8HA)
FSX
Delayed Data
Oct 23, 2026, 06:00 AM
Day's Range
0.500052 wk Range
0.2495Overview - 8HA - Arch Biopartners Inc.
Key Statistics
Valuation
Enterprise Value
23.17M
P/E (Trailing)
-18.83
PEG Ratio
-0.25
Price / Book
-7.70
EV / EBITDA
-18.66
Profitability
Profit Margin
0.00%
Operating Margin
0.00%
Return on Assets
-954.27%
Return on Equity
40.00%
Ownership
Shares Outstanding
67.93M
Float
53.72M
Held by Insiders
18.17%
Held by Institutions
0.00%
Price stats
Beta
1.80
50-Day Avg
0.5405
200-Day Avg
0.4687
Dividends
Payout Ratio
0.00%
Market Cap - 8HA - Arch Biopartners Inc.
Peers - 8HA - Arch Biopartners Inc.
Peer Comparison
Compared with companies in Biotechnology listed on FSX.
- 8HAFSX8HA30.70MMarket Cap+41.84%52-week change-18.83P/E (Trailing)0.00%Profit Margin
- ANLFSXAnalog Devices, Inc.166.10BMarket Cap+40.40%52-week change47.41P/E (Trailing)29.78%Profit Margin
- 0QFFSXModerna Inc.75.83BMarket Cap+88.13%52-week change25.27P/E (Trailing)-141.42%Profit Margin
- 1AEFSXargenx SE46.38BMarket Cap+7.13%52-week change36.55P/E (Trailing)32.26%Profit Margin
- 64BFSXAstera Labs, Inc.45.97BMarket Cap+48.68%52-week change176.19P/E (Trailing)30.74%Profit Margin
- 1AEAFSXargenx SE American Depositary Receipt45.90BMarket Cap-5.00%52-week change32.46P/E (Trailing)32.26%Profit Margin
- 42ZFSXRevolution Medicines, Inc.35.79BMarket Cap+70.06%52-week change-28.07P/E (Trailing)0.00%Profit Margin
Profile Summary - 8HA - Arch Biopartners Inc.
About
Arch Biopartners Inc. is a Canadian therapeutic biotechnology company focused on developing novel drug candidates to prevent and treat kidney-related injury and disease. Headquartered in Toronto, it concentrates on both acute kidney injury and chronic kidney disease, conditions that represent a significant burden in…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
